Clinical Trial Update: Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study [Phase 3]

View source ↗

Summary

A Phase 3 trial (MAIN-CAV) is evaluating the addition of cabozantinib to the immunotherapy drug avelumab for metastatic urothelial cancer, with the study curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma
• Urothelial Carcinoma of the Bladder
• Urothelial Carcinoma of the Renal Pelvis
• Urothelial Carcinoma of the Ureter
• Urothelial Carcinoma of the Urethra

Drugs mentioned

• BAVENCIO (AVELUMAB)
• Cabometyx (cabozantinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING